Boilève A, De Cuyper A, Larive A, et al. - Researchers investigated whether hepatic arterial infusion (HAI)-oxaliplatin plus systemic chemotherapy and targeted therapies (cetuximab/panitumumab or bevacizumab) has feasibility, safety and efficacy in the treatment of unresectable colorectal liver metastases (CRLM). This study involved 89 patients (median age 55 years) who previously underwent a median number of one systemic chemotherapy regimen (range, 0–5), including oxaliplatin in 78% of cases. The intent-to-treat objective response rate was estimated to be 42%, and stable disease was seen in 45%, permitting complete CRLM resection/ablation in 27% of cases. Median overall and progression-free survival was identified to be 20 and 9 months, respectively, following a median follow-up of 72 months. Overall, findings showed the feasibility and safety of a treatment strategy that involved addition of targeted therapy to systemic chemotherapy combined with HAI-oxaliplatin as well as demonstrated the promising activity of this treatment regimen even after systemic chemotherapy failure.